Royalty Report: Drugs, Delivery, Pain – Collection: 291115

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 8

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8

Primary Industries

  • Drugs
  • Delivery
  • Pain
  • Drug Discovery
  • Time-released
  • Disease
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 291115

License Grant
Licensor of Ireland grants to the Licensee, an entity formed by the Licensor and Licensee parent, for the term of the Agreement an exclusive license, with the right to grant sublicenses, for the territory to clinically test, register, have manufactured in accordance with the terms of this Agreement, to package, use, promote, distribute and sell the product  as a prescription medicine.

Licensor grants a non-exclusive license, with the right to grant sublicenses, in the territory for the term to use the Licensor trademark upon or in relation to the product.

License Property
Product shall mean the encapsulated SODAS® drug specific dosage forms in not more than four dosage strengths not exceeding 180mg.

The drug specificed for this agreement is Once-daily oral morphine capsules, containing SODAS® beads.

The trademark shall mean SODAS®.

The Product to be supplied to Licensee by Licensor shall be in the form of bulk two-piece hard gelatin capsules containing microparticulate SODAS® particles.

SODAS® (Spheroidal Oral Drug Absorption System) is Licensor’s Multiparticulate drug delivery system. Based on the production of controlled release beads, the SODAS® technology is characterized by its inherent flexibility, enabling the production of customized dosage forms that respond directly to individual drug candidate needs.

Field of Use
The license is  for a controlled release oral morphine pain relief product.

Licensor is knowledgeable in the development of drug specific dosage forms and has developed a unique range of delivery systems designed to provide newer and better formulations of medicaments,

IPSCIO Record ID: 273586

License Grant
Licensor grants an exclusive license of the Licensor KnowHow to package, use, offer for sale and sell the Product in the Territory.
License Property
Licensor has rights to technology in relation to the development and production of drug specific dosage forms.

Licensor is knowledgeable in the development of drug specific oral and transdermal dosage forms and has developed a unique range of delivery systems designed to provide newer and better formulations of medicaments.

Field of Use
The Licensee entered into a licensing agreement to market a clonidine transdermal patch, a generic version of Catapres TTS®.
Catapres-TTS (clonidine) transdermal therapeutic system is a square, tan adhesive patch containing an active blood-pressure-lowering medication. It is designed to deliver the drug into the body through the skin smoothly and consistently for one full week.

IPSCIO Record ID: 273266

License Grant
Pursuant to an asset purchase agreement also dated July 21, 2004, the Buyer/Licensee acquired rights granted to another, the Third Party, by Licensor of Switzerland.  With this agreement, Licensor agrees to the assignment and assumption of the license.

The Third Party hereby assigns to Buyer all of The Third Party’s rights under or pursuant to the License Agreement relating to Products and Improvements in the Territory.

License Property
The Assignment / Assumption relates to microparticulate capsule formulation of Product (the MPC Formulation), and, Zanaflex tablets. Zanaflex Capsules are manufactured using The Third Partys proprietary SODAS (spheroidal oral drug absorption system) multiparticulate drug delivery technology.

Zanaflex Capsules and Zanaflex tablets contain tizanidine hydrochloride, or tizanidine, one of the two leading treatments currently used for the management of spasticity.

This medication is used to treat muscle spasms caused by certain conditions (such as multiple sclerosis, spinal cord injury).

Field of Use
Zanaflex is a prescription medicine used to treat the symptoms of muscle stiffness (spasticity) associated with conditions such as Cerebral palsy or other neurological disorders.

Licensee is a commercial-stage biopharmaceutical company which markets Zanaflex Capsules.  Zanaflex Capsules and Zanaflex tablets, are FDA-approved for the management of spasticity, a symptom of conditions such as MS and SCI that is commonly characterized by stiffness and rigidity, restriction of movement and painful muscle spasms.

IPSCIO Record ID: 282865

License Grant
For the Research License, Licensor grants an exclusive license under the Licensor Intellectual Property Rights and the Formulation, in the Territory to use the CTM, or clinical trial material, manufactured by Licensor to conduct the Clinical Studies required to file and maintain the Regulatory Filings.

For the Commercial License, Licensor grants an exclusive license under the Licensor Intellectual Property Rights in the Territory to use, offer for sale, import and sell the Product. Licensor grants a license under the  Intellectual Property Rights, in the Territory to make, and have made, the Product to the extent permitted under the Commercial Supply Agreement.

Licensor grants a non-exclusive license to use, and sublicense the right to use, the Licensor Trademarks in the sale and marketing of the Product provided the Product has been manufactured by, on behalf of, or under a license from Licensor.

License Property
Licensor is the owner or licensee of certain technology including processes, patents, trade secrets, trademarks and know-how for the development and manufacture of orally administered pharmaceutical formulations, including controlled release technologies.

DIFFUCAPS® Trademarks

This agreement is for the development of a once-a-day controlled release (CR) capsule dosage form containing a combination of dextromethorphan hydrobromide (DM) and quinidine sulfate (Q). The new product, Neurodex CR, is projected to have 60 mg of DM and up to 60 mg of Q and will be based on Licensors proprietary multi-particulate Diffucaps® technology. Diffucaps beads will allow separate adjustment of the DM and Q doses based on the fill volume of beads in the capsules.

The API or active pharmaceutical ingredients are dextromethorphan hydrobromide or quinidine sulfate separately, or dextromethorphan hydrobromide and quinidine sulfate together.

Product means the pharmaceutical dosage form resulting from the Formulation developed by Licensor pursuant to this agreement.

Formulation means both the identification and selection of ingredients, including the Drug Combination, and the Licensor Patent Rights and Know-How solely related to the Product and improvements thereto.

Field of Use
The field of use is orally administered pharmaceutical formulations, including controlled release technologies.  Diffucaps® incorporate release-controlling polymers or protective coatings onto drug-layered cores, granules, or crystals with one or more drugs.

IPSCIO Record ID: 273417

License Grant
The parties set forth the terms and conditions pursuant to which Licensor will supply for sale to Licensee, and Licensee will purchase from Licensor and market the Product(s) in the Territory based on Licensor’s New Drug Application (NDA)(s).
License Property
Product(s) shall mean either the Valproic Acid EnteriCareâ„¢ Product or the Valproic Acid Versatrolâ„¢ Product, or both of them, in Packaged Product form, which are intended for resale for the Agreement Indications.

Valproic Acid EnteriCare™ Product shall mean enteric release soft gelatin capsules containing the Active Ingredient in the dosage strengths and dosage forms for the Valproic Acid EnteriCare™ Product described in Agreement and made using Licensor’s EnteriCare™ technology.

EnteriCare technology creates a seamless, one-piece design that is uniquely tamper-evident.

Valproic Acid Versatrol™ Product shall mean extended release soft gelatin capsules containing the Active Ingredient in the dosage strengths and dosage forms for the Valproic Acid Versatrol™ Product described in Agreement and made using Licensor’s Versatrol™ technology.

Versatrolâ„¢ controlled release softgel technology uses a standard softgel shell combined with lipid assisted drug delivery, enhancing the absorption of poorly soluble compounds.

Packaged Product shall mean quantities of Product(s) packaged in retail size containers or as physician samples, as the case may be, and not intended for repackaging or re-labeling under the Act.

Intellectual Property shall mean any patent, patent application, trademark, service mark, trade name, trade dress, copyright, trade secret, proprietary know-how, discovery, development or invention, whether or not patentable.

Field of Use
Valproic acid is used to treat certain types of seizures (epilepsy) and bipolar disorder and helps prevent migraine headaches.

IPSCIO Record ID: 248396

License Grant
Licensor grants to Licensee an exclusive license, even as to Licensor, with the right to grant sublicenses, under the Licensor Licensed Technology to use, make, have made, develop, have developed, offer to sell, sell, have sold, distribute, import or otherwise dispose of Licensed Products in the Field in the Territory.

Licensor grants to Licensee and its permitted sublicensees and Affiliates a non-exclusive license to the Licensor Trademarks identified during the term of this Agreement for the purpose of performing its obligations under this Agreement.  The Trademarks are to be used in labeling of Licensed Product as requested as well as use name and derivations thereof in promoting, marketing and selling of Licensed Product in the Territory.

License Property
Licensed Product shall mean oral disintegrating tablets containing prednisolone sodium phosphate, prednisolone, or any salt or base thereof and all improvements and line extensions thereof.

Oral Disintegrating Tablets shall mean a solid tablet dosage form containing medicinal substances which disintegrates rapidly, usually within a matter of seconds when taken orally.

Trademarks shall mean the trademarks, tradenames (and registrations and applications therefor) controlled by each of the parties and used on Licensed Product, (Oral Disintegrating Tablets) including, initially the applicable Licensor Trademarks listed hereto and the applicable Ascent Trademarks listed hereto.
CIMA
CIMA LABS INC.
OraSolv®
PakSolv®
DuraSolv®
CIMA
ORA.FRED®

Licensor Technical Information shall mean (a) techniques and data, including ideas, inventions (including patentable inventions, but excluding inventions covered by Licensor Licensed  Patents), practices methods, knowledge, know-how, trade secrets, skill, experience, documents, apparatus, test data, including pharmacological, toxicological and clinical test data, analytical and quality control data, manufacturing, patent data or descriptions relating to Licensed Product, including, but not limited to, those that relate to DuraSolv(R)Technology, PakSolv(R)Technology and/or OraSolv(R)Technology, owned or Controlled by Licensor and/or its Affiliates and (b) chemical formulations, compositions of matter, product samples and assays relating to Licensed Product, including, but not limited to, those that relate to DuraSolv(R)Technology, PakSolv(R)Technology and/or OraSolv(R)Technology, owned or Controlled by Licensor and/or its Affiliates. Licensor Technical Information shall include Developed Intellectual Property. Licensor Technical Information shall not include any Work Product.

Licensor Licensed Patents shall mean the patents and patent applications owned or Controlled by Licensor and/or its Affiliates that claim Licensed Product, the DuraSolv(R) Technology, the PakSolv(R) Technology and/or the OraSolv(R) Technology as related to Licensed Product, and its manufacture, its packaging, or its use, its import or its sale and including any extension, reissue, renewal, reexamination or continuation-in-part of such patents or patent applications. Licensor Licensed Patents shall include Developed Intellectual Property. Licensor Licensed Patents shall not include any Work Product. The initial list of Licensor Licensed Patents is set forth.

U.S. Pat. No. 5,178,878 – Effervescent dosage form with microparticles
U.S. Pat. No. 6,155,423 – Blister package and packaged tablet
U.S. Pat. No. 6,024,981 – Rapidly dissolving robust dosage form
U.S. Pat. No. 6,221,392 – Rapidly dissolving robust dosage form

DuraSolv(R)Technology shall mean the fast-dissolving drug delivery system generally described in U.S. Patents 6,024,981 and 6,221,392 and PCT Published Application No. WO 98/46215.

PakSolv(R)Technology shall mean the packaging system generally described in U.S. Patents 6,155,423; 6,269,615 and 6,311,462.

OraSolv(R)Technology shall mean the fast-dissolving drug delivery system generally described in U.S. Patent 5,178,878 and U.S. Patent Application 08/468,913.

Field of Use
Field shall mean the treatment of all human conditions.  Exclusive Field shall mean any product containing prednisolone sodium phosphate, prednisolone, or any salt or base thereof.

IPSCIO Record ID: 319516

License Grant
Licensee entered into an exclusive global license and sub-license from the Israel Licensor for the rights to discover, make, sell, market, and otherwise commercialize Licensed Compound or any pharmaceutical composition or preparation (in any and all dosage forms) in final form, including any combination product, containing a Licensed Compound (Licensed Product).
License Property
Licensed Compound means bupivacaine liposome, in injectable gel or suspension.

Licensed Product means any pharmaceutical composition or preparation (in any and all dosage forms) in final form such as LBL100 or ProbudurTM.

LBL100 or ProbudurTM means Long-acting Bupivacaine Liposomal-gel 3.0% which is a drug product candidate based on a unique liposomal delivery system utilizing large multi-vesicular vesicles (“LMVVs”) encapsulating a high dose of the local anesthetic bupivacaine. These drug-loaded liposomes are composed of lecithin and cholesterol which are generally recognized as safe (“GRAS”) by the FDA. These LMVVs are embedded in hydrogel beads to form a Lipogel. The system delivers a local anesthetic/analgesic medicine from the Lipogel. This this product candidate could potentially eliminate the need for opioids for post-operative pain relief.

Probudur is the product candidate covered by US Patent No. 9,713,591. The patent contains composition claims to pharmaceutical compositions having an external storage solution containing an active pharmaceutical ingredient and particles of liposomes embedded in a polymeric matrix contained within the storage solution.

9,713,591 – Composition of matter comprising liposomes embedded in a polymeric matrix and methods of using same

Licensor develops a number of highly-potent therapeutics utilizing proprietary liposome-based nano-drugs with novel drug-loading-capabilities and drug-release mechanisms. Licensors proprietary platform implements a highly-efficient innovative approach which allows for the remote drug loading into nano-liposomes and concomitant controlled release of the drugs at the targeted site.

Field of Use
The field of use is for the treatment of pain control to be used for general surgeons, anesthesiologists, and orthopedic surgeons. Probudur may provide pain control for up to 96 hours.

LBL100 (3% bupivacaine in Lipogel), is being developed as a long-acting local anesthetic for post-operative pain.

LBL100 is a drug product based on a type of liposomal delivery system with large multi-vesicular vesicles (LMVVs) encapsulating a very high dose of the local anesthetic bupivacaine in a unique way. These drug-loaded liposomes are composed of lecithin and cholesterol; both lipids are “GRAS” (Generally Recognized As Safe). These LMVVs are embedded in hydrogel beads to form a lipogel. The system delivers a local analgesic medicine from the Lipogel that is intended to provide improved onset, duration and peak performance properties. With early studies indicating it can provide pain control for up to 96 hours, the formulation has shown the potential to reduce reliance on opioid pain management to improve quality of care and hospital economics.

IPSCIO Record ID: 26627

License Grant
The Licensor grants a limited license to use CDT to manufacture, package, ship, distribute and sell the Products to Customers, as defined below, in the United States in accordance with and for the Term of this Agreement (the License).
License Property
Our CDT (Controlled Delivery Technology) platform currently consists of three patented drug delivery technologies for prescription drugs, over-the-counter (OTC) products, and nutraceuticals.  The CDT platform is used in solid oral dosage forms, the preferred route for drug administration. This technology is designed to produce tablets or capsules that release their active agents predictably and programmable over a specified time frame of up to 24 hours.
Field of Use
Licensee manufactures and distributes vitamins and dietary and nutritional supplements for various third party customers.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.